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The Ross procedure achieved an established position in thetreatment of congenital aortic valve disease.1 However,right ventricular outflow tract (RVOT) reconstruction stilllimits this procedure. We describe a patient with recurrent
aortic valve stenosis after repeated surgical and interventional proce-
dures. The Ross operation was performed, and the RVOT was recon-
structed using a tissue-engineered (TE) heart valve.
Clinical Summary
A 23-year-old woman with congenital bicuspid aortic valve stenosis
was referred to our department for recurrence of left ventricular–aortic
pressure gradient after multiple surgical and interventional procedures
at other hospitals. Chronologically, the patient underwent closure of
the patent ductus arteriosus at birth, resection of a subaortic membrane
and open valvotomy 5 years later, closure of iatrogenic ventricular
septal defect during the next year, and new open valvotomy with
closure of the residual ventricular septal defect at the age of 14 years.
The following year a percutaneous balloon aortic valvotomy was
performed. After the last procedure, the medical history was unre-
markable until the patient started to have palpitations, evening asthe-
nia, and recurrent incipient syncopes at 21 years of age. Paroxysmal
supraventricular tachyarrhythmia caused by atrial flutter was demon-
strated by 24-hour electrocardiography. Transthoracic echocardiogra-
phy (TTE) demonstrated a maximal left ventricular-aortic pressure
gradient of 87 mm Hg, an aortic valve orifice area of 0.7 cm2, and
normal ejection fraction with mild concentric hypertrophy of the left
ventricle. The interventional ablation of atrial flutter was performed
before surgery to prevent postoperative recurrent supraventricular
tachyarrhythmia. Granting the request of the patient to avoid any
anticoagulants, we proposed to implant a TE heart valve during the
Ross procedure. Informed consent was obtained. Construction of a TE
heart valve was previously exhaustively reported.2 Briefly, endothe-
lial cells were harvested, isolated, and cultured. One week before
implantation, a 25-mm cryopreserved pulmonary allograft was
decellularized and seeded by a sedimentation technique. The op-
eration was performed with normothermic cardiopulmonary by-
pass using warm-blood cardioplegia. The autograft was implanted
using the root replacement technique, and the reconstruction of the
RVOT was performed with the TE heart valve in a no-touch
technique. The postoperative course was uneventful. The patient
was discharged with instructions to take only 100 mg of acetyl-
salicylic acid daily. Follow-up was performed by TTE, magnetic
resonance imaging, and multislice computed tomography angiog-
raphy, according to a protocol previously published.2 Thirty-six
months after the operation, the patient is in New York Heart
Association class I without any restrictions of her activities. Dur-
ing follow-up, TTE showed no regurgitation and minimal mean
pressure gradients in both valves (Figure 1). These findings were
supported by magnetic resonance imaging, which showed stable
aortic and pulmonary pressure gradients, and left ventricular mass
and volume reduction. The multislice computed tomography dem-
onstrated no calcifications on both heart valves and showed
smoothly moving leaflets without any retraction (Figure 2).
Discussion
The Ross procedure is widely used for treating aortic valve disease
in children because of the growth potential of the pulmonary
autograft, physiologic hemodynamic properties, negligible preva-
lence of infection, and absence of anticoagulation.1 The recon-
struction of the RVOT has been generally performed using a
pulmonary allograft. However, allografts represent nonviable
structures and lack the ability to grow, repair, or remodel. Further-
more, they are subject to calcification and structural degeneration,
mainly because of specific humoral and cellular immunologic
response against type I and II histocompatibility antigens.3 Al-
though the underlying pathophysiologic mechanism is not com-
pletely known, other factors could be involved, such as a nonim-
munologic-mediated adventitial fibrotic inflammatory reaction
causing extrinsic compression of the conduit and an early postop-
erative stretching and lengthening of the homograft causing release
of tissue factors responsible for an unspecific inflammatory reac-
tion.4 The TE heart valves could overcome these limitations.
Decellularization significantly reduces the tissue antigenicity with-
out interfering with extracellular matrix integrity, which could
enhance long-term durability.3 Excellent hemodynamic perfor-
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doi:10.1016/j.jtcvs.2006.12.023 Figure 1. Echocardiographic evaluation of aortic and pulmonary
valve mean pressure gradients. TE, tissue engineered.
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degeneration, was shown. The process of endothelial cells seeding
recreates a physiologic barrier that could reduce the procoagula-
tory activity of bare matrix components exposed to the blood. It is
noteworthy that the potential for remodeling, regeneration, and
growth of a decellularized allograft was proved in the juvenile
sheep model.5
TE heart valves may represent an excellent option to recon-
struct the RVOT during the Ross operation. However, long-term
follow-up is needed to establish the superiority of these valves.
References
1. Al-Halees Z, Pieters F, Qadoura F, Shahid M, Al-Amri M, Al-Fadley F.
The Ross procedure is the procedure of choice for congenital aortic
valve disease. J Thorac Cardiovasc Surg. 2002;123:437-42.
2. Dohmen PM, Lembcke A, Hotz H, Kivelitz D, Konertz WF. Ross
operation with a tissue engineered heart valve. Ann Thorac Surg.
2002;74:1438-42.
3. da Costa FD, Dohmen PM, Duarte D, von Glenn C, Lopes SV, Filho
HH, et al. Immunological and echocardiographic evaluation of decel-
lularized versus cryopreserved allografts during the Ross operation. Eur
J Cardiothorac Surg. 2005;27:572-8.
4. Zehr KJ, Yagubyan M, Connolly HM, Nelson SM, Schaff HV. Aortic
root replacement with a novel decellularized cryopreserved aortic ho-
mograft: postoperative immunoreactivity and early results. J Thorac
Cardiovasc Surg. 2005;130:1010-5.
5. Dohmen PM, da Costa F, Holinski S, Lopes SV, Yoshi S, Reichert LH,
et al. Is there a possibility for a glutaraldehyde-free porcine heart valve
to grow? Eur Surg Res. 2006;38:54-61.
Figure 2. Multislice computed tomography: absence of calcifica-
tion and tissue degeneration with smooth pliable valve leaflets of
the TE heart valve after 3 years. TE, tissue engineered.
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